Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GERON CORPGERN · Entity 4989 | Director | May 21, 2025 | May 22, 2025 |
| Unicycive Therapeutics, Inc.UNCY · Entity 6568 | Director | August 25, 2025 | August 26, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GERON CORP
Report date May 21, 2025 · Filed May 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2035-05-20 | Direct | 180,000 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 180,000 · Balance 180,000 F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates.
Unicycive Therapeutics, Inc.
Report date August 25, 2025 · Filed August 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Vivo Opportunity Fund Holdings L.P. | 1,789,915 |
Reported balance
After 2025-08-25 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-08-25 · Conversion · Acquired 652,900 · Balance 1,789,915 F1: Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $4.90, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024. F2: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Series A-2 Prime Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.90 | IndirectBy Vivo Opportunity Fund Holdings L.P. | 0 |
Reported balance
After 2025-08-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-25 · Disposition to issuer · Disposed 3,199.21 · Balance 0 F3: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date. F2: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $4.90, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024.
F2: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F3: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sierra Oncology, Inc.
Report date July 01, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy: Vivo Opportunity Fund Holdings, L.P. | 0 |
Reported balance
After 2022-07-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-07-01 · Disposition to issuer · Disposed 2,735,853 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc ("GSK"), Orikum Acquisition Inc. ("Merger Sub") and the Issuer (the "Merger Agreement"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the "Merger"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest. F2: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.87 · Expires 2029-11-29 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-01 · Disposition to issuer · Disposed 1,500 · Balance 0 F4: At the effective time of the Merger, each stock option outstanding, whether vested or unvested, automatically and without any required action on the part of the Reporting Person, was cancelled in exchange for the right to receive an amount in cash equal to the excess, if any, of $55.00 over the per share exercise price of such stock option. F3: The option fully vested on November 29, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-01 · Disposition to issuer · Disposed 6,874 · Balance 0 F4: At the effective time of the Merger, each stock option outstanding, whether vested or unvested, automatically and without any required action on the part of the Reporting Person, was cancelled in exchange for the right to receive an amount in cash equal to the excess, if any, of $55.00 over the per share exercise price of such stock option. F5: The option fully vested on June 9, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.11 · Expires 2031-06-08 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-01 · Disposition to issuer · Disposed 6,000 · Balance 0 F4: At the effective time of the Merger, each stock option outstanding, whether vested or unvested, automatically and without any required action on the part of the Reporting Person, was cancelled in exchange for the right to receive an amount in cash equal to the excess, if any, of $55.00 over the per share exercise price of such stock option. F6: The option fully vested on June 8, 2022. |
| Series A WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $13.20 · Expires 2024-11-13 | IndirectBy: Vivo Opportunity Fund Holdings, L.P. | 0 |
Reported balance
After 2022-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-07-01 · Disposition to issuer · Disposed 1,455,384 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the "Series A Warrants") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants. F2: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc ("GSK"), Orikum Acquisition Inc. ("Merger Sub") and the Issuer (the "Merger Agreement"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the "Merger"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest.
F2: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F3: The option fully vested on November 29, 2020.
F4: At the effective time of the Merger, each stock option outstanding, whether vested or unvested, automatically and without any required action on the part of the Reporting Person, was cancelled in exchange for the right to receive an amount in cash equal to the excess, if any, of $55.00 over the per share exercise price of such stock option.
F5: The option fully vested on June 9, 2021.
F6: The option fully vested on June 8, 2022.
F7: Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the "Series A Warrants") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2025 Filed Aug 26, 2025 17:06 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | Disposition to issuerSeries A-2 Prime Preferred Stock · Derivative | 3,199.21 | $1,000.00 Strike: $4.90 | $3,199,210.00 |
DisclosureSEC source: 0001213900-25-080808 · ownership.xml · derivative · entry 2 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings L.P. Disclosed balance after: 0 Underlying: Common Stock · 652,900 shares Expires not disclosed F3 · derivative.exercise_date: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date. F3 · derivative.expiration_date: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date. F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 17:06 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | ConversionCommon Stock | 652,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-080808 · ownership.xml · nonDerivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings L.P. Disclosed balance after: 1,789,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $4.90, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024. F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 16:30 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 21,200 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001213900-25-069306 · ownership.xml · derivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,200 Underlying: Common Stock · 21,200 shares Expires 2035-07-28 Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:07 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0000886744-25-000027 · wk-form4_1747948046.xml · derivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2035-05-20 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 11:55 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | Disposition to issuerSeries A-2 Prime Preferred Stock · Derivative | 686 | $1,000.00 Strike: $0.49 | $686,000.00 |
DisclosureSEC source: 0001213900-25-015152 · ownership.xml · derivative · entry 2 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings L.P. Disclosed balance after: 3,119.21 Underlying: Common Stock · 1,400,000 shares Expires not disclosed F3 · derivative.exercise_date: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date. F3 · derivative.expiration_date: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date. F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 11:55 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | ConversionCommon Stock | 1,400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-015152 · ownership.xml · nonDerivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings L.P. Disclosed balance after: 11,370,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $0.49, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024. F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 09, 2024 Filed Oct 10, 2024 17:15 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | Disposition to issuerSeries A-2 Prime Preferred Stock · Derivative | 2,695 | $1,000.00 Strike: $0.49 | $2,695,000.00 |
DisclosureSEC source: 0001213900-24-086928 · ownership.xml · derivative · entry 2 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings L.P. Disclosed balance after: 3,885.21 Underlying: Common Stock · 5,500,000 shares Expires not disclosed F3 · derivative.exercise_date: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date. F3 · derivative.expiration_date: The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date. F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| October 09, 2024 Filed Oct 10, 2024 17:15 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | ConversionCommon Stock | 5,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-086928 · ownership.xml · nonDerivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings L.P. Disclosed balance after: 9,970,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $0.49, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024. F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| May 09, 2024 Filed May 10, 2024 20:05 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000950170-24-057800 · ownership.xml · derivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2034-05-08 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| December 29, 2023 Filed Jan 4, 2024 00:02 UTC | GERON CORP GERN · Entity 4989 | GrantCommon Stock | 1,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000545 · doc4.xml · nonDerivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,970 F1 · kind: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of the Issuer's Common Stock on December 29, 2023 of $2.11 per share. F1 · price: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of the Issuer's Common Stock on December 29, 2023 of $2.11 per share. Read SEC document |
| November 26, 2023 Filed Nov 28, 2023 21:10 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001209191-23-056767 · doc4.xml · derivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-11-25 F1 · derivative.exercise_date: This option vests in a series of three equal consecutive annual installments commencing from November 26, 2023, subject to the non-employee director providing continuous service to the Company through each vesting date. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 16:30 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 180,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001213900-23-075008 · ownership.xml · derivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2033-09-05 Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 20:42 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | ConversionTranche C Warrants (right to buy) · Derivative | 18,621,655 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001213900-23-056885 · ownership.xml · derivative · entry 6 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 18,621,655 Underlying: Series A-5 Preferred Stock · 18,621,655 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date. F4 · derivative.exercise_date: The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones. F4 · derivative.expiration_date: The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones. F3 · derivative.underlying: Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 20:42 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | ConversionTranche B Warrants (right to buy) · Derivative | 11,638,534 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001213900-23-056885 · ownership.xml · derivative · entry 5 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 11,638,534 Underlying: Series A-4 Preferred Stock · 11,638,534 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date. F4 · derivative.exercise_date: The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones. F4 · derivative.expiration_date: The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones. F3 · derivative.underlying: Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 20:42 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | ConversionTranche A Warrants (right to buy) · Derivative | 12,802,388 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001213900-23-056885 · ownership.xml · derivative · entry 4 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 12,802,388 Underlying: Series A-3 Preferred Stock · 12,802,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date. F4 · derivative.exercise_date: The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones. F4 · derivative.expiration_date: The Tranche A Warrants, Tranche B Warrants and Tranche C Warrants are immediately exercisable for shares of Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock, respectively, and will each expire upon the Issuer's satisfaction of certain milestones. F3 · derivative.underlying: Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 20:42 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | ConversionSeries A-2 Preferred Stock · Derivative | 13,429,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-056885 · ownership.xml · derivative · entry 3 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 13,429,000 Underlying: Common Stock · 13,429,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date. F1 · kind: On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date. F3 · derivative.exercise_date: Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date. F3 · derivative.expiration_date: Each of the Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock (collectively, the "Preferred Stock") is convertible into Common Stock on a one-for-one basis; however, the Preferred Stock is subject to blocking provisions which preclude such shares from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer's voting securities. The shares of Preferred Stock have no expiration date. F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 20:42 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | ConversionSeries A-1 Preferred Stock · Derivative | 8,077 | $1,000.00 Strike: $0.49 | $8,077,000.00 |
DisclosureSEC source: 0001213900-23-056885 · ownership.xml · derivative · entry 2 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 0 Underlying: Common Stock · 59,961,729 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date. F1 · kind: On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date. F1 · derivative.exercise_date: On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date. F1 · derivative.expiration_date: On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date. F1 · derivative.underlying: On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date. F1 · derivative.underlying_shares: On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date. F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 20:42 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | ConversionCommon Stock | 3,470,152 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-056885 · ownership.xml · nonDerivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 3,470,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date. F1 · price: On July 11, 2023, the 8,077 shares of Series A-1 Preferred Stock then held by Vivo Opportunity Fund Holdings, L.P. automatically converted into (i) 3,470,152 shares of Common Stock, (ii) 13,429,000 shares of Series A-2 Preferred Stock, (iii) Tranche A Warrants to purchase 12,802,388 shares of Series A-3 Preferred Stock, (iv) Tranche B Warrants to purchase 11,638,534 shares of Series A-4 Preferred Stock and (v) Tranche C Warrants to purchase 18,621,655 shares of Series A-5 Preferred Stock. The shares of Series A-1 Preferred Stock had no expiration date. F2 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 21:39 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantSeries A-1 Convertible Preferred Stock · Derivative | 8,077 | $1,000.00 Strike: $0.49 | $8,077,000.00 |
DisclosureSEC source: 0001213900-23-018973 · ownership.xml · derivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 8,077 Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · derivative.exercise_price: The Conversion Price of the Series A-1 Preferred Stock is subject to adjustment as set forth in that certain of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock attached as Exhibit 3.1 to the Issuer's Form 8-K filed with the Securities and Exchange Commission on March 6, 2023 (the "Certificate of Designation"). Capitalized terms that are used but not defined in this Form 4 have the meanings given to them in the Certificate of Designation. F2 · derivative.exercise_date: The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant. F3 · derivative.expiration_date: The shares of Series A-1 Convertible Preferred Stock have no expiration date. F4 · derivative.expiration_date: The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation. F2 · derivative.underlying: The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant. F4 · derivative.underlying: The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation. F2 · derivative.underlying_shares: The shares of Series A-1 Convertible Preferred Stock are not convertible until the stockholders of the Issuer approve the Proposals. Additionally, on the Automatic Conversion Date, as set forth in the Certificate of Designation, each share of Series A-1 Preferred Stock shall automatically convert into a unit consisting of (1) shares of Common Stock (or shares of Series A-2 Preferred Stock) equal to the quotient of (A) the Liquidation Preference divided by (B) the Conversion Price, (2) a Tranche A Warrant, (3) a Tranche B Warrant and (4) a Tranche C Warrant. F4 · derivative.underlying_shares: The Tranche A Warrants are exercisable for Series A-3 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche B Warrants are exercisable for Series A-4 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. The Tranche C Warrants are exercisable for Series A-5 Preferred Stock and expire upon the Issuer's satisfaction of certain milestones. All shares of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series A-5 Preferred Stock have no expiration date and are convertible into shares of Common Stock in accordance with the Certificate of Designation. F5 · ownership.nature: Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:45 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerSeries A Warrant · Derivative | 1,455,384 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001209191-22-040279 · doc4.xml · derivative · entry 5 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,455,384 shares Expires 2024-11-13 F7 · price: Pursuant to the terms of the Merger Agreement, the Issuer's outstanding Series A Warrants (the "Series A Warrants") were treated in accordance with their respective terms such that, at the effective time of the Merger, the outstanding Series A Warrants were cancelled and thereafter represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants), which as calculated under the terms of the Series A Warrants equaled $45.98 per share of common stock underlying such warrants. F2 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:45 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001209191-22-040279 · doc4.xml · derivative · entry 4 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2031-06-08 F4 · price: At the effective time of the Merger, each stock option outstanding, whether vested or unvested, automatically and without any required action on the part of the Reporting Person, was cancelled in exchange for the right to receive an amount in cash equal to the excess, if any, of $55.00 over the per share exercise price of such stock option. F6 · derivative.exercise_date: The option fully vested on June 8, 2022. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:45 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 6,874 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001209191-22-040279 · doc4.xml · derivative · entry 3 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,874 shares Expires 2030-06-09 F4 · price: At the effective time of the Merger, each stock option outstanding, whether vested or unvested, automatically and without any required action on the part of the Reporting Person, was cancelled in exchange for the right to receive an amount in cash equal to the excess, if any, of $55.00 over the per share exercise price of such stock option. F5 · derivative.exercise_date: The option fully vested on June 9, 2021. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:45 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $13.87 | $0.00 |
DisclosureSEC source: 0001209191-22-040279 · doc4.xml · derivative · entry 2 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2029-11-29 F4 · price: At the effective time of the Merger, each stock option outstanding, whether vested or unvested, automatically and without any required action on the part of the Reporting Person, was cancelled in exchange for the right to receive an amount in cash equal to the excess, if any, of $55.00 over the per share exercise price of such stock option. F3 · derivative.exercise_date: The option fully vested on November 29, 2020. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:45 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerCommon Stock | 2,735,853 | $55.00 | $150,471,915.00 |
DisclosureSEC source: 0001209191-22-040279 · doc4.xml · nonDerivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Vivo Opportunity Fund Holdings, L.P. Disclosed balance after: 0 F1 · shares: Pursuant to an Agreement and Plan of Merger, dated April 12, 2022, between GlaxoSmithKline plc ("GSK"), Orikum Acquisition Inc. ("Merger Sub") and the Issuer (the "Merger Agreement"), Merger Sub merged with and into the Issuer on July 1, 2022, with the Issuer surviving as a wholly-owned subsidiary of GSK (the "Merger"). At the effective time of the Merger, each outstanding share of common stock of the Issuer automatically and without any required action on the part of the Reporting Person, was converted into the right to receive $55.00 in cash, without interest. F2 · ownership.nature: Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P., the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 31, 2022 Filed Jan 31, 2022 18:47 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | PurchaseCommon Stock | 800,000 | $27.00 | $21,600,000.00 |
DisclosureSEC source: 0001209191-22-005748 · doc4.xml · nonDerivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo Opportunity Fund, L.P. Disclosed balance after: 2,735,853 F1 · ownership.nature: The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund, L.P. The Reporting Person may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. with four other managing members of Vivo Opportunity, LLC. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 19:53 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherSeries B Warrant (Right to Purchase) · Derivative | 1,455,384 | $13.20 Strike: $13.20 | $19,211,068.80 |
DisclosureSEC source: 0001209191-22-005503 · doc4.xml · derivative · entry 2 Aggarwal Gaurav · CIK 0001551965 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo Opportunity Fund, L.P. Disclosed balance after: 0 Underlying: Common Stock · 480,277 shares Expires not disclosed F2 · derivative.expiration_date: The expiration date of the warrants is the date on the seventy-fifth (75th) day anniversary of the announcement by Issuer, via publicly disseminated press release or SEC filing, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis. F1 · ownership.nature: The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund, L.P. The Reporting Person may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. with four other managing members of Vivo Opportunity, LLC. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 19:53 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | OtherCommon Stock | 480,277 | $13.20 | $6,339,656.40 |
DisclosureSEC source: 0001209191-22-005503 · doc4.xml · nonDerivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo Opportunity Fund, L.P. Disclosed balance after: 1,935,853 F1 · ownership.nature: The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund, L.P. The Reporting Person may be deemed to share voting and dispositive power over the securities held by Vivo Opportunity Fund, L.P. with four other managing members of Vivo Opportunity, LLC. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 10:29 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right To Buy) · Derivative | 6,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001209191-21-039089 · doc4.xml · derivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The Option fully vests and becomes exercisable on June 8, 2022, subject to the Reporting Person's provision of service to the Issuer as of the vesting date. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 18:58 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 6,874 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001209191-20-035686 · doc4.xml · derivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,874 Underlying: Common Stock · 6,874 shares Expires 2030-06-09 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 9, 2020, with 100% of the total shares vested and exercisable on June 9, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 16:56 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | ConversionSeries A Convertible Voting Preferred Stock · Derivative | 19,213 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-005792 · doc4.xml · derivative · entry 2 Aggarwal Gaurav · CIK 0001551965 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo Opportunity Fund, LP Disclosed balance after: 0 Underlying: Common Stock · 1,455,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date. F4 · shares: Consists of 19,213 shares of Series A Preferred Stock held by VOF which are convertible into an aggregate of 1,455,576 shares of Common Stock, as adjusted for the Reverse Split. F2 · price: Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date. F2 · derivative.exercise_date: Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date. F2 · derivative.expiration_date: Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date. F1 · derivative.underlying_shares: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F3 · ownership.nature: The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund, L.P. ("VOF"). The Reporting Person may be deemed to share voting and dispositive power over the securities held by VOF with four other managing members of Vivo Opportunity, LLC. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 16:56 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | ConversionCommon Stock | 1,455,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005792 · doc4.xml · nonDerivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Vivo Opportunity Fund, LP Disclosed balance after: 1,455,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F2 · price: Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the Reverse Split following November 13, 2019. The Series A Preferred Stock has no expiration date. F1 · balance_after: On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split. F3 · ownership.nature: The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund, L.P. ("VOF"). The Reporting Person may be deemed to share voting and dispositive power over the securities held by VOF with four other managing members of Vivo Opportunity, LLC. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 16:15 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001209191-19-058686 · doc4.xml · derivative · entry 1 Aggarwal Gaurav · CIK 0001551965 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-11-29 F1 · date: Stock options were granted on November 29, 2019 in connection with the Reporting Person's appointment to the Issuer's Board of Directors on November 22, 2019. F2 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on December 29, 2019, with 100% of the total shares vested and exercisable on November 29, 2020, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.